What do systematic reviews say?

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Sclerotherapy (STS) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1.49 [0.99, 2.25]
  4 studies · 409 participants
  Moderate

Sclerotherapy vs placebo

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 2.44 [1.69, 3.55]
  1 study · 596 participants
  Low

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 480 participants
  Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 348 participants
  Moderate

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Sclerotherapy (chromated glycerin) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1.5 [0.3, 7.55]
  1 study · 26 participants
  Low

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in pain ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.83, 1.24]
  2 studies · 191 participants
  Moderate

Foam vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 147 participants
  Low

Laser therapy vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 100 participants
  Low